close
Add to watchlist
Cortex Pharmaceuticals Inc (COR) Healthcare, Biotechnology & Drugs
Cortex Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The company develops AMPAKINE compounds for the treatment of Alzheimer's disease, mild cognitive impairment, attention deficit hyperactivity disorder, schizophrenia, depression, respiratory depression caused by opiate analgesics, and possibly sleep apnea. Its low impact AMPAKINE compounds include CX717 and CX1739, which are in phase II clinical development stage; and high impact compounds include CX929 for Huntington's disease patients. The company has a research collaboration and exclusive worldwide license agreement with NV Organon to develop and commercialize its AMPAKINE technology for the treatment of schizophrenia and depression. Cortex Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 22.77 |
| Volume | 130588 |
| Volume Avg | 197452 |
| 52 Week High | 22.98 |
| 52 Week Low | 12.34 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.24 |
| EPS change Q/Q | -6.25% |
| EPS change Q/Q Yr ago | -240% |
| EPS change Q/Q next Q est | 1000% |
| EPS change Y/Y | -88.37% |
| REV change Q/Q | 4.17% |
| REV change Q/Q Yr ago | 344.44% |
| EPS next Q est | 0.34 |
| EPS next Y est | 1.62 |
| Divident Annual | 0.57 |
| Dividend Yield | 2.5% |